Hepatoma Research

Topic: Emerging Relationships between the Gut Microbiome and Liver Cancer

Download All Articles Special Issue Flyer

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 15 Oct 2020

Guest Editor(s)

Mark Alan Feitelson, MD, PhD

Professor, Molecular, Cellular, and Developmental Biology, Department of Biology, Temple University, USA.

Website | E-mail

Special Issue Introduction

The gut microbiome is now considered an organ system which is central to maintaining metabolic and immunological homeostasis. It is involved in the production of compounds necessary for life, for the metabolism of many compounds that are ingested, and stimulates innate and adaptive immunity on the one hand, while tempering immune responses on the other. Alterations in the composition of bacteria (and other microbes) in the gut in a condition known as dysbiosis, are associated with an increasing and remarkable number of diseases characterized by chronic inflammation affecting multiple organ systems, including the liver. Hepatocellular carcinoma (HCC) is one of the many tumor types arising on a background of chronic inflammation. Importantly, HCC arises from many etiologies, including hepatitis B and C virus infections, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, alcoholic liver disease, as well as autoimmune hepatitis and from several genetic abnormalities. While it is not clear whether dysbiosis contributes to the cause or is the outcome of HCC, manipulation of the gut microbiome will likely help to re-establish the homeostasis. There is a long way to go, but there is no question that rebalancing the gut microbiome will be essential to recovering health as nature intended it.

Participants

1. Nahum Mendez-Sanchez & Ludovico Abenavoli Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Department of Health Sciences, University "Magna Graecia" Viale Europa, Catanzaro 88100, Italy.
2. Jian Wu, Chang Liu & Ning-Ping Zhang Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China.
3. Jin Zhou Program of Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore.
4. Ilchom T. Murkamilov First President of Russia B.N.Yeltsin Kyrgyz Russian Slavic University, Bishkek, Kyrgyzstan.
The list is arranged in no particular order and being updated.

Submission Deadline

15 Oct 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/hr
Submission Deadline: 15 Oct 2020
Contacts: Ada Zhong, Assistant Editor, editor_Ada@hrjournal.net

Published Articles

Open Access Review

The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer

Nahum Méndez-Sánchez, ... David Q.-H. Wang

Currently, alcoholic liver disease (ALD) is one of the most prevalent chronic liver diseases worldwide, representing one of the main etiologies of cirrhosis and hepatocellular carcinoma (HCC). Although we do not know the exact mechanisms by which only a selected group of patients with ALD... Read More >

Currently, alcoholic liver disease (ALD) is one of the most prevalent chronic liver diseases worldwide, representing one of the main etiologies of cirrhosis and hepatocellular carcinoma (HCC). Although we do not know the exact mechanisms by which only a selected group of patients with ALD progress to the final stage of HCC, the role of the gut microbiota within the progression to HCC has been intensively studied in recent years. To date, we know that alcohol-induced gut dysbiosis is an important feature of ALD with important repercussions on the severity of this disease. In essence, an increased metabolism of ethanol in the gut induced by an excessive alcohol consumption promotes gut dysfunction and bacterial overgrowth, setting a leaky gut. This causes the translocation of bacteria, endotoxins, and ethanol metabolites across the enterohepatic circulation reaching the liver, where the recognition of the pathogen-associated molecular patterns via specific Toll-like receptors of liver cells will induce the activation of the nuclear factor kappa-B pathway, which releases pro-inflammatory cytokines and chemokines. In addition, the mitogenic activity of hepatocytes will be promoted and cellular apoptosis will be inhibited, resulting in the development of HCC. In this context, it is not surprising that microbiota-regulating drugs have proven effectiveness in prolonging the overall survival of patients with HCC, making attractive the implementation of these drugs as co-adjuvant for HCC treatment.
Back >

This article belongs to the Special Issue Emerging Relationships between the Gut Microbiome and Liver Cancer

Hepatoma Res 2020;6:5.

DOI: 10.20517/2394-5079.2019.29

Published on: 20 Feb 2020 Viewed: 704 Downloaded: 172

View Full-Text Download PDF